Kolon Life Science

Kolon Life Science will continue to pursue its dream of becoming a specialized global enterprise and a leading cell and gene therapy company in the future. It aims to achieve this goal by promoting development, with its biopharmaceutical business built on the growth and profitability of its fine chemical operations, including active pharmaceutical ingredients (APIs), specialty chemicals, and aqueous solutions. The company has developed the world's first new drug in cell and gene form for the treatment of degenerative arthritis. In addition, Kolon Life Science is also committed to enhancing research capabilities in areas such as neuropathic painkillers and anticancer drugs within the field of genetic medicine.